Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL.

Leukemia
Keenan T HartertAnne J Novak

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma, and front line therapies have not improved overall outcomes since the advent of immunochemotherapy. By pairing DNA and gene expression data with clinical response data, we identified a high-risk subset of non-GCB DLBCL patients characterized by genomic alterations and expression signatures capable of sustaining an inflammatory environment. These mutational alterations (PIM1, SPEN, and MYD88 [L265P]) and expression signatures (NF-κB, IRF4, and JAK-STAT engagement) were associated with proliferative signaling, and were found to be enriched in patients treated with RCHOP that experienced unfavorable outcomes. However, patients with these high-risk mutations had more favorable outcomes when the immunomodulatory agent lenalidomide was added to RCHOP (R2CHOP). We are the first to report the genomic validation of a high-risk phenotype with a preferential response towards R2CHOP therapy in non-GCB DLBCL patients. These conclusions could be translated to a clinical setting to identify the ~38% of non-GCB patients that could be considered high-risk, and would benefit from alternative therapies to standard RCHOP based on personalized genomic data.

References

Jan 25, 2002·The New England Journal of Medicine·Bertrand CoiffierChristian Gisselbrecht
Jun 1, 2002·Science·David S Aaronson, Curt M Horvath
Aug 17, 2005·Advances in Immunology·Louis M Staudt, Sandeep Dave
Apr 28, 2006·Nature Genetics·Michael ReichJill P Mesirov
May 20, 2006·Bioinformatics·Joshua GouldJill P Mesirov
Mar 8, 2008·Science·Georg LenzLouis M Staudt
Sep 4, 2008·Proceedings of the National Academy of Sciences of the United States of America·Georg LenzLouis M Staudt
May 5, 2009·Nature·Motohiro KatoSeishi Ogawa
May 26, 2009·Nucleic Acids Research·Jing ChenAnil G Jegga
Dec 2, 2010·Blood·Sietse M AukemaPhilip M Kluin
Dec 24, 2010·Nature·Vu N NgoLouis M Staudt
Jan 14, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T E WitzigM S Czuczman
Oct 22, 2013·G3 : Genes - Genomes - Genetics·Jennifer HardeeMichael Snyder
Feb 20, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matthew J MaurerJames R Cerhan
Mar 14, 2014·The New England Journal of Medicine·David A Fruman, Lewis C Cantley
Mar 15, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R Vaidya, T E Witzig
Aug 20, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Grzegorz S NowakowskiThomas E Witzig
Feb 26, 2015·Nature Reviews. Immunology·Katia Basso, Riccardo Dalla-Favera
Jul 21, 2015·Nature Medicine·Wyndham H WilsonLouis M Staudt
Jul 22, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John G GribbenFranck Morschhauser
Dec 10, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ryan D MorinNathalie A Johnson
May 22, 2016·Bioinformatics·Zuguang GuMatthias Schlesner
Dec 8, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sydney DuboisFabrice Jardin
Apr 12, 2018·The New England Journal of Medicine·Roland SchmitzLouis M Staudt
Aug 15, 2018·The Journal of Immunology : Official Journal of the American Association of Immunologists·Georg AueAdrian Wiestner

❮ Previous
Next ❯

Citations

Feb 18, 2021·Experimental Hematology & Oncology·Philippe DecruyenaereJo Vandesompele
May 1, 2021·Cancers·Benedetto Daniele GiaimoTilman Borggrefe

❮ Previous
Next ❯

Methods Mentioned

BETA
exome sequencing

Clinical Trials Mentioned

NCT00670358

Software Mentioned

nanoString
PanCan
GenePattern
ToppGene
RCHOP
Gene Neighbor analysis
BWA
MEM
Hans
GATK

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.